Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Last trade$135.92
Day change-$1.09 (-0.80%)
Day range$132.30 – $137.91
Volume217,299
Market cap$7.21B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$7.21B
Price / earnings
—
Price / book
68.35×
Price / sales
8.33×
EV / sales
8.19×
EV / EBITDA
-49.19×
Profitability
Earnings per share
-$2.99
Return on assets
-19.02%
Return on equity
-149.19%
Dividend yield
0%
Liquidity and leverage
Debt / equity
1.87×
Current ratio
1.42×
Quick ratio
1.34×
Cash ratio
0.62×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$82.61M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for AXSM, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$259.69M
$218.38M
$191.2M
$196M
$170.99M
$150.04M
$121.46M
$118.77M
Cost of revenue
$17.8M
$13.56M
$14.73M
$12.33M
$11.91M
$13.45M
$9.79M
$10.51M
Gross profit
$241.89M
$204.81M
$176.48M
$183.67M
$159.08M
$136.59M
$111.67M
$108.25M
Selling, general and administrative
$203.11M
$208.14M
$185M
$169.3M
$150.24M
$130.28M
$120.79M
$113.27M
Research and development
$50.62M
$46.23M
$52.68M
$48.79M
$40.16M
$49.54M
$44.79M
$55.01M
Total operating expenses
$252.96M
$254.46M
$239.84M
$210.63M
$205.19M
$173.31M
$168.66M
$180.87M
Operating income
-$11.07M
-$49.65M
-$63.36M
-$26.96M
-$46.11M
-$36.71M
-$56.98M
-$72.62M
Interest expense
-$1.72M
-$1.54M
$0
$0
-$1.12M
-$1.83M
$0
$0
Income before taxes
-$12.79M
-$51.19M
-$64.54M
-$28.13M
-$47.23M
-$48.93M
-$59.41M
-$74.83M
Income taxes
$88K
$128K
$0
$430K
$0
-$960K
$0
$85K
Net income
-$12.88M
-$51.31M
-$64.54M
-$28.56M
-$47.23M
-$47.97M
-$59.41M
-$74.91M
Net income attributable to common shareholders
-$12.88M
-$51.31M
-$64.54M
-$28.56M
-$47.23M
-$47.97M
-$59.41M
-$74.91M
EBITDA
-$9.33M
-$47.91M
-$61.67M
-$25.24M
-$44.38M
-$35.01M
-$55.26M
-$70.88M
Basic earnings per share
-$0.25
-$0.99
-$1.26
-$0.56
-$0.94
-$0.97
-$1.22
-$1.54
Diluted earnings per share
-$0.25
-$0.99
-$1.26
-$0.56
-$0.94
-$0.97
-$1.22
-$1.54
Recent news
Company coverage with links to the original publishers.
Axsome Therapeutics and Moderna represent different biotech investment profiles. Axsome shows strong 54% revenue growth with three marketed drugs and a narrowing path to profitability, trading at conservative valuations (41x forward P/E). Moderna, despite its revolutionary mRNA platform, faces declining COVID vaccine demand and significant losses ($2.8B net loss on $2.5B revenue), trading at a premium 249x forward P/E. The article recommends Axsome as the better 2027 buy due to superior valuation and near-term revenue visibility, while acknowledging Moderna's long-term potential.
Following a 5% Nasdaq decline after midterm elections, the article recommends two stocks for long-term investors: Shopify, which is leveraging AI-powered tools to drive strong revenue growth and capitalize on e-commerce expansion, and Axsome Therapeutics, a biotech company with strong performance from its depression and Alzheimer's drug Auvelity and a promising pipeline of new products.
Axsome Therapeutics (AXSM) reported a quarterly loss of $0.25 per share, beating consensus estimates of $0.69 loss by 63.77%, with revenues of $259.69 million exceeding expectations by 5.37%. However, the stock has underperformed the market, declining 20.9% year-to-date versus the S&P 500's 10.7% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.
Axsome Therapeutics has demonstrated steady quarter-over-quarter revenue growth, surpassing Moderna's quarterly revenue by Q2 2026 despite starting from a much smaller base. Meanwhile, Moderna has experienced significant revenue volatility, with sharp declines following peaks, largely due to reduced COVID-19 vaccine adoption and underperforming RSV vaccine sales. Axsome's three-drug portfolio shows promise with multiple clinical trials underway, while Moderna faces challenges from overreliance on products that have lost market traction.
Rhythm Pharmaceuticals (RYTM) is expected to beat Q3 2026 earnings estimates with a positive Earnings ESP of +1.38% and Zacks Rank #3. The company is projected to report a quarterly loss of $0.68 per share (improved from $0.81 year-ago) with revenues of $84.47 million, up 64.7% year-over-year. The stock has beaten consensus EPS estimates in 3 of the last 4 quarters.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.